11.03

1.38% +0.15

Pre-market: 11.03

Roivant Sciences Ltd (ROIV)

Overview News Price History Option Chain Why ROIV Down? Discussions Forecast

Roivant Sciences Ltd stock is currently priced at $11.03, with a 24-hour trading volume of 3.10M. It has seen a +1.38% increased in the last 24 hours and a +9.42% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $10.77 pivot point. If it approaches the $11.16 resistance level, significant changes may occur.

Previous Close:

$10.88

Open:

$10.95

24h Volume:

3.10M

Market Cap:

$8.89B

Revenue:

$123.24M

Net Income/Loss:

$4.47B

P/E Ratio:

-8.2313

EPS:

-1.34

Net Cash Flow:

$-838.55M

1W Performance:

+5.45%

1M Performance:

+9.42%

6M Performance:

+30.53%

1Y Performance:

+27.66%

1D Range:

$10.88

$11.11

52W Range:

$8.06

$13.24

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name

Roivant Sciences Ltd

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

44 4412 955 950

Address

11-12 St. Jamesâ€™s Square, 15th Floor 11-12 St. Jamesâ€™s Square, London

Employee

620

Twitter

Next Earnings Date

2024-02-13

Latest SEC Filings

ROIV's Discussions on Twitter

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Outperform
Jan-05-24	Initiated	Piper Sandler	Overweight
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-17-23	Initiated	Guggenheim	Buy
Jun-08-23	Initiated	BofA Securities	Neutral
Oct-27-22	Initiated	JP Morgan	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight
Dec-15-21	Initiated	Goldman	Buy
Nov-08-21	Initiated	H.C. Wainwright	Buy
Oct-28-21	Initiated	Citigroup	Buy
Oct-26-21	Initiated	Cowen	Outperform
Oct-26-21	Initiated	Jefferies	Buy
Oct-26-21	Initiated	Truist	Buy

View All

Roivant Sciences Ltd Stock (ROIV) Latest News

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024

GlobeNewswire Inc.

Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations

Benzinga

Assessing Roivant Sciences: Insights From 5 Financial Analysts

Benzinga

Roivant Sciences Ltd Stock (ROIV) Financials Data

Roivant Sciences Ltd (ROIV) Revenue 2024

ROIV reported a revenue (TTM) of $123.24 million for the quarter ending December 31, 2023, a +185.76% rise year-over-year.

Roivant Sciences Ltd (ROIV) Net Income 2024

ROIV net income (TTM) was $4.47 billion for the quarter ending December 31, 2023, a +458.61% increase year-over-year.

Roivant Sciences Ltd (ROIV) Cash Flow 2024

ROIV recorded a free cash flow (TTM) of -$838.55 million for the quarter ending December 31, 2023, a -1.14% decrease year-over-year.

Roivant Sciences Ltd (ROIV) Earnings per Share 2024

ROIV earnings per share (TTM) was $5.20 for the quarter ending December 31, 2023, a +392.13% growth year-over-year.

Roivant Sciences Ltd Stock (ROIV) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Venker Eric	President & COO	Feb 09 '24	Option Exercise	3.85	96,950	373,258	629,157
Venker Eric	President & COO	Feb 09 '24	Sale	10.92	96,950	1,058,694	532,207
Ramaswamy Vivek	10% Owner	Jan 02 '24	Sale	11.05	3,000,000	33,150,000	51,929,426
Venker Eric	Chief Operating Officer	Oct 05 '23	Sale	10.11	153,027	1,547,103	595,397
Venker Eric	Chief Operating Officer	Oct 04 '23	Option Exercise	3.85	153,027	589,154	748,424
Venker Eric	Chief Operating Officer	Oct 03 '23	Option Exercise	3.85	606,221	2,333,951	1,201,618
Venker Eric	Chief Operating Officer	Oct 03 '23	Sale	10.25	606,221	6,213,765	595,397
Venker Eric	Chief Operating Officer	Oct 02 '23	Option Exercise	3.85	440,752	1,696,895	1,036,149
Roivant Sciences Ltd.	Director	Oct 02 '23	Buy	38.00	1,526,316	58,000,008	79,805,331
Venker Eric	Chief Operating Officer	Oct 02 '23	Sale	10.80	440,752	4,760,122	595,397

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.